

Special Issue

Metallodrugs in Cancer Therapy: The Newest Candidates in the Field, 2nd Edition

Message from the Guest Editors

Metal ions play key roles in a myriad of biological processes known to be essential to life. Living organisms have developed mechanisms to maintain cellular levels of metal ions, which are tightly regulated; excess or deficiency in these ions result in disease, including cancer disorders. The use of metals and their compounds as medicines has been known since ancient times, even though insight into their modes of action was merely empiric, and the distinction between a therapeutic or toxic dose was a major challenge. This Special Issue is intended to collect recent research/discoveries in the field of cancer prospective metallopharmaceuticals. This is an area in constant evolution, and we welcome submissions on subjects including, but not limited to: Synthetic methods/characterization and biological activity of novel metal-based compounds; Structure–activity studies; Drug delivery for metal-based compounds; Metal complexes overcoming MDR (metallodrug resistance to treatment); Mode of action, uptake, cell targets and (cyto)toxicity; Metal complexes as theranostics; Biospeciation of metal ions and anti-cancer metal-based compounds.

Guest Editors

Dr. Ana Isabel Tomaz

Dr. Andreia Marques Valente

Dr. Leonor Côrte-Real

Deadline for manuscript submissions

closed (20 November 2024)



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/171955

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy,
Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1
(Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).